ec2
 

Lindsay
Rosenwald

Founder of the Rosenwald Foundation

New York

Widely considered a leading figure in the field of biotechnology and pharmaceutical investing, Lindsay Rosenwald has worked with some of the most innovative companies in the world, bringing their industry-changing products into the next phases of development. With a diversified background as a health care management consultant and practicing physician, Dr. Rosenwald entered the booming market for biotechnology in the mid-1980s as a Wall Street financial and medical analyst. Lindsay Rosenwald subsequently launched an investment company, which he quickly grew into a multifaceted source of financing, management consulting, and other necessary services for the drug development sector.

Lindsay Rosenwald has distinguished his group of companies by identifying and financing a vast array of biotechnology firms with potentially revolutionary drugs in clinical trials. Among these, he has founded or invested in Cypress Bioscience,Coronado Biosciences, Enzymed, Keryx Bio-pharmaceuticals,Ziopharm Oncology,and Cougar Biotechnology, which sold to Johnson & Johnson in 2009 for nearly $1 billion. At the top of Genetic Engineering & Biotechnology News’ 2002 list of Molecular Millionaires, Dr. Rosenwald has also gained distinction as a Director of Keryx Biopharmaceuticals, a cofounder of OpusPoint Partners, and a philanthropic leader.

The founder of the Rosenwald Foundation, Lindsay Rosenwald has donated millions of dollars to a number of worthy charitable initiatives through this organization. Dr. Rosenwald is also an Honorary Member of the Board of Visitors at the Smeal College of Business at The Pennsylvania State University and has been part of the Columbia-Presbyterian Health Sciences Advisory Council.Dr. Rosenwald is also a member of the Board of Visitors of the Temple University School of Medicine.


Lindsay Rosenwald's Schools

Lindsay Rosenwald's Companies

Lindsay Rosenwald's Publications

  • Arsenic Trioxide in the Treatment of Leukemia
    May, 2013
    Dr. Lindsay Rosenwald, an experienced physician and an early leader among medical practitioners who joined the Wall Street investment advisory community, has started or contributed to the growth of a wide range of companies in the pharmaceutical and biotechnology investment sector. In one of his small start-up companies, he played an instrumental part in developing the antineoplastic drug arsenic trioxide, which has over the last decade gained the confidence of physicians who battle acute promyelocytic leukemia. The disease had previously been viewed as extremely challenging to treat.

    Through his company and its research staff, Dr. Lindsay Rosenwald devoted extensive time and expertise to work on arsenic trioxide, which now may be used to treat patients with cancers beyond APL. The drug works by blocking the growth of cancer cells. Physicians believe that the changes it sets into motion end by destroying the diseased cells. The drug may work to stop the progression of APL at its source by correcting the gene that creates the defective protein responsible for the development of the disease in the first place.

    Arsenic trioxide is administered intravenously in a series of as many as 60 sessions until the patient’s bone marrow ceases to record the presence of leukemia cells. A 2012 paper distributed through the United States National Library of Medicine’s National Center for Biotechnology Information reported that the drug causes few side effects and has been responsible for long-lasting remission in at least half of the patients studied who suffered from relapsed APL. The United States Food and Drug Administration approved arsenic trioxide in 2000.

    [Sources:
    http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/arsenic-trioxide
    http://www.ncbi.nlm.nih.gov/pubmed/21904379
    http://www.mayoclinic.com/health/drug-information/DR600183 ]